ASH 2023 | Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a retrospective study that investigated the impact of hematological response to frontline treatment on overall survival (OS) in lower-risk myelodysplastic syndromes (LR-MDS). Over 600 patients were included in the analysis, which showed that response rates were higher with erythroid stimulating agents (ESA) as frontline than with any second-line therapy. Hematological improvement with front- or second-line therapy was associated with improved OS, and lack of response to frontline therapy was associated with a poorer OS. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Aprea, Jazz
Consultancy: AbbVie, Affimed Gmbh, Gilead, Incyte, Intellisphere, LLC, Molecular Partners AG, PGEN Therapeutics, Inc., Takeda, Zentalis; Advisory board for AvenCell, BlueBird Bio, BMS, Intellia, Jasper Therapeutics, Kite, Magenta Therapeutics, NKARTA, Novartis, Orbita
